BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sunshine Biopharma, Inc. Narrows Kilogram Manufacturing Options for Adva-27a Breast Cancer Drug Candidate to Three Suppliers


5/1/2013 11:55:21 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MONTREAL--(Marketwired - May 01, 2013) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, is pleased to report that following negotiations with several Contract Manufacturing Organizations ("CMOs") for the GMP (Good Manufacturing Practice) manufacturing of one kilogram of Adva-27a breast cancer drug candidate, the Company has narrowed the field of contenders to three CMOs. While there are timeframe variations among these three manufacturers, largely related to the availability of their large scale chemical reactors at the time we place our order, overall it will take approximately 10 to 14 weeks for a one kilogram GMP synthesis of Adva-27a to be delivered to us.

The Company anticipates that one kilogram of Adva-27a will be sufficient to complete the upcoming IND-Enabling animal toxicity studies and Phase I clinical trials. These are required to be performed using the same GMP manufactured material. Following completion of the animal toxicity studies, the Company expects to file an Investigational New Drug (IND) application with the FDA (U.S. Food and Drug Administration) and wait for authorization to proceed with the planned Phase I clinical trial scheduled to be hosted at McGill University's Jewish General Hospital in Montreal, Canada. The Company intends to make any leftover material available for "compassionate-use" programs that allow seriously-ill cancer patients gain access to the drug candidate.

"We are excited to be at the stage of conducting GMP manufacturing of our drug," said Dr. Steve N. Slilaty, President and Chief Executive Officer of Sunshine Biopharma. "The filing of our process patent to protect Adva-27a manufacturing in January this year allowed us to quickly move forward and securely share information with CMO's to supply us with kilogram quantities of Adva-27a to complete the data for the IND application and conduct Phase I clinical trials.

About Breast Cancer

The National Cancer Institute ("NCI") estimates that 232,340 women and 2,240 men in the United States will be diagnosed with breast cancer in 2013. According to the NCI website, approximately 40,000 deaths in 2013 will be attributed to breast cancer, making it the second leading cause of cancer related deaths in women in the United States. Globally, 1.38 million new cases of breast cancer were diagnosed in 2008 and 458,000 deaths resulted from the disease, according to the World Health Organization. One of the most commonly used drugs to treat breast cancer today is Herceptin® (trastuzumab), a therapeutic of Roche Holding AG designed to treat patients with HER-2 (Human Epidermal Growth Factor Receptor 2) positive form of the disease. This condition is present in approximately 20 percent of breast cancer patients. Sales of Herceptin® in 2012 were approximately $6 billion worldwide.

About Sunshine Biopharma Inc.

Sunshine Biopharma is a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma's parent company, Advanomics Corporation, recently announced that it has filed a new patent application covering various composition matters and manufacturing processes of Adva-27a.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


For Additional Information Contact:
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES